MedPath
HSA Approval

TANSTRIVE HARD CAPSULES 40MG

SIN16990P

TANSTRIVE HARD CAPSULES 40MG

TANSTRIVE HARD CAPSULES 40MG

April 24, 2024

DKSH SINGAPORE PTE. LTD.

Regulatory Information

DKSH SINGAPORE PTE. LTD.

Therapeutic

Prescription Only

Formulation Information

CAPSULE

ORAL

Medical Information

L01EX22

selpercatinib

Manufacturer Information

DKSH SINGAPORE PTE. LTD.

Lilly del Caribe, Inc.

Lilly, S.A. (Primary and Secondary Packager)

Active Ingredients

Selpercatinib

40.0mg

Selpercatinib

Documents

Package Inserts

Tanstrive Hard Capsule PI.pdf

Approved: April 24, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TANSTRIVE HARD CAPSULES 40MG - HSA Approval | MedPath